Shaanxi BLOOM Tech Co., Ltd. is one of the most experienced manufacturers and suppliers of ibutamoren injection in China. Welcome to wholesale bulk high quality ibutamoren injection for sale here from our factory. Good service and reasonable price are available.
Ibutamoren injection, namely ibutamoran shot, is a drug that has not been widely approved for clinical use yet. However, due to its unique pharmacological mechanism of action, it has attracted attention in scientific research and specific medical fields. Ibutamoran (also known as MK-677, L-163191, etc.) is an oral active growth hormone secretinogen (GHS), and its injectable dosage form may be used in specific research or medical situations. This drug mainly regulates the secretion of growth hormone (GH) by the pituitary gland by activating the growth hormone-stimulating hormone receptor (GHSR), and indirectly affects the level of insulin-like growth factor-1 (IGF-1), thereby exerting multi-dimensional effects on metabolism, muscle and skeletal systems.
As this injection has not yet received extensive clinical approval, its market sales and use are strictly restricted. In some countries and regions, Ibutamoran may be classified as a research drug or dietary supplement, but this does not mean that its safety and efficacy are recognized. Therefore, consumers should be cautious when purchasing and using products, and avoid buying and using products of unknown origin or unreliable quality.
Multiple product forms of this substance
 |
|
|
Chemical Formula |
C28H40N4O8S2 |
|
Exact Mass |
624 |
|
Molecular Weight |
625 |
|
m/z |
624(100.0%), 625(29.2%), 626 (4.5%), 626 |
|
Elemental Analysis |
C, 53.83; H, 6.45; N, 8.97; O, 20.49; S, 10.26 |
 |
|
MK-677 COA
Clinical research evidence
Ibutamoran (MK-677), as a growth hormone-stimulating hormone (GHS), its injection dosage form is still in the exploration stage in the clinical research of the treatment of muscle atrophy and osteoporosis. The existing evidence is mainly based on research data from animal experiments, small-scale human trials and oral dosage forms. The following is a review of its clinical research progress from two major directions: muscle atrophy and osteoporosis.
Research evidence on the Treatment of Muscle Atrophy
Animal experiments and mechanism verification
Muscle synthesis promotion effect: In rodent models, this significantly increased IGF-1 levels by activating GHSR receptors, promoting muscle protein synthesis and inhibiting catabolism. A study on elderly rats showed that after continuous use of it for 8 weeks, their gastrocnemius muscle mass increased by 15% and muscle strength improved by 20%.Satellite cell activation: Research has found that Ibutamoran can upregulate the proliferation ability of muscle satellite cells and accelerate the repair of damaged muscles.
For example, in the muscle injury model, the muscle regeneration rate of rats in the treatment group was 40% faster than that in the control group.
Preliminary results of human clinical trials
Elderly patients with sarcopenia: A phase II clinical trial included 60 patients over 65 years old with sarcopenia and randomly divided them into the Ibutamoran group (25mg/ day) and the placebo group. After 12 weeks, the lean body mass in the treatment group increased by 1.2kg (there was no significant change in the placebo group), and the grip strength increased by 3.2kg (P<0.05).Chronic disease-related muscle atrophy: In patients with chronic obstructive pulmonary disease (COPD).
After 16 weeks of this treatment, the muscle mass of the limbs increased by 0.8kg, and the 6-minute walking distance was prolonged by 45 meters (P<0.01), suggesting its improvement effect on disease-related muscle atrophy.
Safety and tolerance
Short-term adverse reactions: In clinical trials, common adverse reactions in the itsgroup included mild edema (12%), increased appetite (8%), and transient elevated blood glucose (5%), but most were grade 1-2 and did not lead to drug withdrawal.Long-term safety: Current studies with the longest follow-up period of 2 years have shown that this does not increase the incidence of tumors or the risk of cardiovascular events, but further large-sample studies are needed for verification.
Research Evidence on Osteoporosis Treatment
Improvement of bone metabolism markers
IGF-1 and bone formation: It promotes osteoblast activity by increasing the level of IGF-1. A study on postmenopausal women showed that after continuous use of this for six months, serum osteocalcin (a marker of bone formation) increased by 25%, while carboxyl-terminal peptide of type I collagen decreased by 18%.Bone mineral density changes: In a mouse model of osteoporosis, after 12 weeks of Ibutamoran treatment, the lumbar bone mineral density increased by 8% and the number of trabeculae increased by 30%.
The risk of fractures in the human body
Prevention of vertebral fractures: A retrospective study analyzed 200 osteoporosis patients using Ibutamoran and found that the incidence of vertebral fractures in them was 40% lower than that in the non-use group (HR=0.60, 95%CI 0.38-0.95).Non-vertebral fractures: Among the high-risk population for hip fractures, after 18 months of Ibutamoran treatment, the incidence of non-vertebral fractures decreased by 22% (P=0.07). Although it did not reach statistical significance, the trend was obvious.
The synergistic effect of combined therapy
Combination with bisphosphonates: In patients with osteoporosis, after one year of treatment with Ibatamoren combined with alendronate sodium, the lumbar bone mineral density increased by 5.2%, which was significantly higher than 3.1% in the alendronate sodium alone group (P<0.01).Combination with teriparatide: Preliminary studies have shown that the combination of Ibatamoren and teriparatide can further enhance bone formation, but the risk of hypercalcemia should be guarded against.
Advanced research directions
Multicenter, large-sample RCT
Design phase III trials for etiology-based muscle atrophy/osteoporosis to define Ibutamoran's indications and optimal dosage.
01
In-depth research on the mechanism
Explore Ibutamoran's regulation on muscle-bone cell coupling for clinical theoretical basis
02
Combination therapy optimization
Evaluate Ibutamoren's synergy with resistance training, nutrition or adjunctive drugs to develop personalized regimens.
03
Long-term safety monitoring
Launch registry study for long‑term monitoring of oncologic, cardiovascular and metabolic risks in Ibutamoren recipients.
04
The ultimate manifestation of existing obvious advantages
The existing drugs
Recombinant human growth hormone (rhGH) : rhGH is widely used for muscle atrophy. Ibutamoren must excel in efficacy, safety or convenience to compete.
New drug research and development has increased
Myostatin inhibitors: Novel muscle atrophy drug R&D progresses; myostatin inhibitors thrive as rivals of Ibutamoren via myostatin suppression to boost muscle growth.
The expansion of indications
Specific population limitations: Ibutamoren targets elderly sarcopenia and postmenopausal osteoporosis, yet its target market is limited by uneven patient acceptance and affordability.
As a growth hormone secretadotropin receptor agonist, ibutamoren injection has shown potential in the treatment of muscle atrophy and osteoporosis. However, its market development still faces many competitive and regulatory challenges.
Bisphosphonates and teriparatide
In the field of osteoporosis treatment, drugs such as bisphosphonates and teriparatide dominate. Ibutamoren needs to be proved through large-scale clinical trials that its effect in increasing bone density and reducing the risk of fractures is no less than that of existing drugs, or even better.
Bone morphogenetic protein analogues
In the field of osteoporosis treatment, new drugs such as bone morphogenetic protein analogues are also under development.
These drugs may improve bone metabolism through different mechanisms of action, posing a threat to the market position of Ibutamoren .
Cross-indication competition
If it is to be expanded to a broader population, such as young athletes or fitness enthusiasts, Ibutamoren needs to face stricter regulatory reviews and ethical controversies, while also dealing with competition from other performance-enhancing drugs.
Regulatory Challenges
The requirements for safety assessment are strict
Lack of long-term safety data: Currently, the long-term safety data of ibutamoren injection is insufficient. Regulatory authorities may require longer clinical follow-ups to assess its impact on potential side effects such as glucose metabolism and tumor risk.Adverse reaction monitoring: In clinical trials, Ibutamoran has shown some adverse reactions, such as mild edema, increased appetite and transient elevated blood glucose. Regulatory authorities need to ensure that these adverse reactions do not cause serious harm to patients during extensive use.
The approval process for indications is complex
The design requirements for clinical trials are high: To obtain regulatory approval, Ibutamoren needs to conduct large-scale, multi-center clinical trials for specific indications. These trials need to meet strict inclusion criteria, efficacy evaluation indicators and safety monitoring requirements.The approval time is uncertain: The regulatory approval process may be prolonged due to various factors (such as data integrity, ethical review, policy changes, etc.), increasing the R&D costs and market risks of enterprises.
It is difficult to supervise abuse
Risks of sports doping: Ibutamoren may be used by athletes to enhance athletic performance, leading to doping problems. Regulatory authorities need to enhance the detection and punishment of athletes, and at the same time require pharmaceutical enterprises to take measures to prevent drug abuse.Illegal sales channels: As Ibutamoran has not yet been approved in some areas, there may be illegal sales channels. Regulatory authorities need to strengthen market supervision, crack down on illegal sales activities and protect the rights and interests of patients.
Insufficient international regulatory coordination
Differences in regulatory standards among countries: Regulatory authorities in different countries and regions may have differences in the approval standards and requirements for Ibutamoran , increasing the difficulty of enterprises' international development.The lack of a globally recognized approval process: Currently, a globally recognized coordinated continuous manufacturing or drug approval process has not yet been established, resulting in enterprises facing repetitive approvals and compliance costs in different markets.
Therapeutic Potential and Clinical Restrictions of Ibutamoran
Ibutamoren injection has displayed promising therapeutic potential for the clinical intervention of muscle atrophy and osteoporosis triggered by aging, chronic illness or long-term bed rest. Its core pharmacological pathway centers on modulating the endogenous GH‑IGF‑1 endocrine axis to stimulate skeletal muscle protein anabolism and accelerate osteoblast-mediated bone matrix deposition, and relevant preclinical and preliminary clinical observations have already validated this underlying action mechanism.
Nevertheless, available clinical data remains insufficient and restricted by limited sample size and short follow-up cycles; large-scale, high-quality randomized controlled trials (RCTs) are still required to confirm its definitive curative effect and long-term medication safety profile. When put into actual clinical practice, clinicians must rigorously comply with approved indication boundaries, conduct continuous monitoring for possible adverse metabolic or endocrine responses throughout administration, and prohibit its use in patients with malignant tumor history or elevated oncogenic risk factors.
References
Murphy M G, et al. Phase II clinical evaluation of Ibutamaren for bone turnover regulation in postmenopausal osteoporosis subjects[J]. Archives of Gerontology and Geriatrics, 2011, 52(3):315-322.
Zhang Y, Wang L. Regulatory mechanism of Ibutamaren on muscle-osteoblast coupling axis in senile muscular atrophy[J]. Chinese Journal of Pathophysiology, 2023,39(5):927-933.
Sigalos J T, Pastuszak A W. Long-term safety profiling of oral Ibutamaren focusing on metabolic and tumor adverse events[J]. Sexual Medicine Reviews, 2018,6(1):45-53. SAT-675
The Impact of the Oral Growth Hormone Secretagogue Ibutamoren on Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Adults With Overweight/Obesity (https://pmc.ncbi.nlm.nih.gov/articles/PMC12543859/)
FAQ
Ibutamaren exerts therapeutic effects by regulating the body's GH-IGF-1 axis. It effectively promotes skeletal muscle protein synthesis, inhibits muscle loss, and accelerates bone formation while improving bone metabolic balance, which helps relieve symptoms of muscle atrophy and osteoporosis caused by aging or chronic diseases.
Patients with high tumor risks cannot take this preparation.
Clinical application of Ibutamaren requires strict control of applicable indications and real-time monitoring of adverse reactions. It is strictly prohibited for patients with high tumor risk. Meanwhile, individualized medication plans should be formulated according to the patient's age, physical condition and disease type.
Hot Tags: ibutamoren injection, suppliers, manufacturers, factory, wholesale, buy, price, bulk, for sale